Contemplating a future where machines break free of human meddling, with internet law expert Jonathan Zittrain.

"My child has been attending a major programming school since elementary school for three years and can now create games ...

How do you get from a chatbot that sometimes makes things up to a machine that humans might struggle to control? There are several steps in that argument, and plenty of uncertainty. But an idea known ...

The US-China race for artificial intelligence dominance has entered a new phase: using AI to build better AI. Leading AI companies in the United States and China are increasingly focused on deploying ...

Anthropic and OpenAI researchers raised fresh concerns about recursive self-improvement, the process by which AI helps improve the development of models. Both OpenAI and Anthropic have in recent ...

AI agents are not yet creative enough to carry out genuinely innovative open-ended AI research, it seems. The AI industry’s boldest promise right now is that AI will soon improve itself, with almost ...

Try these simple movements to stay strong and limber. Try these simple movements to stay strong and limber. Credit... Supported by By Danielle Friedman Videos by Theodore Tae In many cases, aches and ...

Recursion Pharmaceuticals, Inc. remains a Hold as competitive advances and slow revenue growth challenge its AI-driven drug discovery ambitions. RXRX's partnerships, notably with Genentech/Roche and ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

The up-to-$12 billion artificial intelligence (AI) drug discovery collaboration of Recursion, Roche, and its Genentech subsidiary marked a milestone Wednesday when plans were announced for Recursion ...

Roche Holding AG advanced the first project from its AI drug-discovery partnership with Recursion Pharmaceuticals, marking an early test of whether artificial intelligence can uncover new medicines.

On Tuesday, the AI company Recursive Superintelligence announced a $410 million compute deal with Amazon Web Services. The company, which emerged from stealth in May with $650 million in funding, is ...